OR: Steps you can take in the clinic to prevent HIV infections

Similar documents
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations

PrEP in the Real World: Clinical Case Studies

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016

PrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014

PrEP: Pre Exposure Prophylaxis

TAKING A HISTORY OF SEXUAL HEALTH: OPENING THE DOOR TO EFFECTIVE HIV AND STI PREVENTION

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

Using anti-hiv drugs for prevention

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

Attendees will be able to:

Pre-Exposure Prophylaxis (PrEP) for HIV Infection

TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

Syphilis among MSM: Clinical Care and Public Health Reporting

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials:

Implementing HIV Prevention in Patient Centered Medical Homes and Primary Care

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

Addressing STIs among MSM: A Clinical and Public Health Update

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

PrEP: Getting to the Tipping Point

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention

Drug development in relation to PrEP and the PROUD study

Objectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.

Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

ART and Prevention: What do we know?

Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico

HIV Prevention among Women

HIV & THE MEDICAL HOME A NEW FRONT FOR GETTING TO ZERO. Brent K. Sugimoto, MD, MPH Kaiser Permanente. 29th Annual East Bay HIV Update June 3, 2016

Modernization of North Carolina s HIV control measures

The HIV Prevention Pill: The State of PrEP Science and Implementation

Program to control HIV/AIDS

Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?

Pre-Exposure Prophylaxis for HIV: The Basics and Beyond

PREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER

Pre-exposure Prophylaxis and Primary Care

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

PREVENTION OF HIV IN THE TIMES OF PREP. Daniela Chiriboga, MD Florida Department of Health in Polk County

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

Fast-Track Your PrEP Knowledge. Jonathan Fritz PrEP Coordinator MDHHS Division of HIV and STD Programs

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Improving Patient Engagement in HIV Care: Health Department Strategies

PEP, PREP, HPTN052 and MLN2238

Pre-exposure Prophylaxis for HIV Prevention

-decreased bone Adherence iprex study. -protective effect

PrEP 201: Beyond the Basics

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination

NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium

Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection

Fertility Desires/Management of Serodiscordant HIV + Couples

Arizona State Office of Rural Health Webinar Series

HIV - Preventing New Infections: New Options, Readjusted Approaches

Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination

HIV. The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV. Brief History of HIV AIDS. Global HIV Infection.

Billing and Coding for HIV Services

PrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?

2016 NYS HIV Quality of Care Review

PrEP for Women: HIV Prevention in Family Planning Settings

ART for HIV Prevention:

Find both sets of guidelines on nyc.gov by searching HIV PrEP and PEP. Per CDC Guidelines, PrEP may be appropriate for the following populations:

Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings

Pre-exposure Prophylaxis (PrEP)

Pre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018

Post-Sexual Exposure Prophylaxis (npep)

The Door is Open PrEP in Practice. Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital

HIV Pre- Exposure Prophylaxis

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

HIV Prevention Pearls

HIV Reproductive Health: Conception Options in the Era of PrEP

Getting to Zero in California: Integration of HIV Prevention and Surveillance

Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012

High Impact Prevention: Science, Practice, and the Future of HIV

Getting to Zero: Reducing HIV Incidence through Screening, Treatment, and Prevention. Learning Module

Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013

Pre-Exposure Prophylaxis against HIV in Primary Care. September 2017 Update. John-Paul Bettencourt, D.O., M.P.H., AAHIVS

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

PrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine

HIV Prevention Strategies HIV Pre-exposure prophylaxis

Understanding the Results of VOICE

I M ENDING HIV PATIENT INFORMATION. endinghiv.org.au/prep

Biomedical Prevention Update Thomas C. Quinn, M.D.

Lessons from MSM PrEP pilots / demonstration projects. Kevin Rebe

Combination HIV Prevention

8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward

Pre-exposure prophylaxis (PrEP)

Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -

Case year old single gay man First contact with clinic in Nov Unprotected sex 60 hours previously Received PEP Remained HIV-negative

Update on PrEP progress: WHO/UNAIDS challenges and actions

Combination prevention: Public health and human rights imperatives

Strategic use of antiretroviral drugs to prevent HIV transmission

Transcription:

Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute OR: Steps you can take in the clinic to prevent HIV infections 1

A person at risk 26-year-old male with no chronic medical problems Sexually active with multiple male partners; rarely uses condoms Most consistent sexual partner is HIVinfected and on antiretroviral therapy Treated in the past for HSV, gonorrhea, and LGV Agenda Conceptualize the integration ti of public health and primary care Discuss two bio-behavioral approaches to HIV prevention Treatment as prevention (TasP) Pre-exposure prophylaxis (PrEP) 2

Public Health assuring conditions in which people can be healthy Surveillance and Outbreak Investigation Policies and Laws Food and Environmental Safety Personal Health Care (Primary and Specialty) IOM 1988 Primary Care Activities BENEFITS PERSONAL HEALTH Colonoscopy HTN treatment BENEFITS POPULATION HEALTH Notifying authorities of reportable conditions BENEFITS PERSONAL AND POPULATION HEALTH Alcohol abuse treatment Vaccinations HIV prevention Treatment of Chlamydia/gonorrhea 3

What prevents HIV transmission? Courtesy of Patrick Sullivan Treatment as Prevention (TasP) Das 2010 4

Treatment as Prevention (TasP) 1,763 serodiscordant couples Early ART Delayed ART (at enrollment) (when CD4 250) 1 transmission 27 transmissions Cohen 2011 Barriers to TasP (and what you can do about them) Lapses in the HIV care continuum 5

Most HIV-infected individuals do not have suppressed viral loads 100 90 80 70 60 50 40 30 20 10 0 HIV-infected Diagnosed Linked to care Retained in care 72 % On ART Viral load < 200 MMWR 2011 Improvement at multiple levels is needed to fix the treatment cascade Gardner 2011 6

Black MSM are less likely to be aware of HIV infection Wejnert CROI 2013 Question: You screen a 35-year-old man for HIV at a routine preventive health care visit. He is sexually active with one male partner. His HIV ELISA is positive, but his Western blot is negative. What should you do? A. Send an HIV-1 viral load B. Send a Western blot for HIV-2 C. Reassure him; this is likely a false (+) result D. Repeat the ELISA/Western blot in 1 month 7

Question: You screen a 35-year-old man for HIV at a routine preventive health care visit. He is sexually active with one male partner. His HIV ELISA is positive, but his Western blot is negative. What should you do? A. Send an HIV-1 viral load B. Send a Western blot for HIV-2 C. Reassure him; this is likely a false (+) result D. Repeat the ELISA/Western blot in 1 month HIV Testing Logistics Window periods impact test accuracy: Viral load: ~10 days post infection 4 th generation Ag/Ab test: ~15 days 3 rd generation EIA: ~20 days Western blot: up to 60 days New testing algorithms may eliminate the Western blot A viral load should be sent if acute HIV is suspected Branson 2010 8

Next steps: Linkage to and Retention in Care 100 90 80 70 60 50 40 30 20 10 0 HIV-infected Diagnosed Linked to care Retained in care On ART Viral load < 200 MMWR 2011 Who is at risk for not engaging in care? Young age Heterosexual identification African-American race Less education Lower income Lack of insurance Injection drug use Mental illness Horstmann 2010 9

What would you do if, while seeing a 42-year-old woman for a sprained ankle, you notice: 1. She had a breast biopsy with invasive ductal carcinoma 8 months ago; she s not seen an oncologist or received any treatment since? 2. She was diagnosed with active pulmonary tuberculosis 8 months ago but has not received treatment? 3. She was diagnosed with HIV 8 months ago (CD4 178, HIV RNA 82,000) and has not seen an HIV provider or begun ARVs? What you can do Promptly link any newly diagnosed HIV patients to HIV care Active versus passive referrals Identify out-of-care persons and do what you can to reconnect them to HIV care Address substance abuse and mental illness 10

Public health-emr information exchanges may facilitate engagement in care 39 year old male with asthma flare Information transmitted to DPH database Identified as HIVinfected with no VL or CD4 in 12 months Linkage to, retention in care Information on the provider s actions sent back to DPH database Clinical alert sent to EMR with decision support tools Louisiana Public Health Information Exchange (LaPHIE) 419 persons identified over 30 months 24% had not had labs since diagnosis Median time out of care = 19 months 42% had CD4 counts < 200 82% had a CD4/VL after identification Herwehe 2012, Magnus 2012 11

Additional Approaches INTERVENTION STEP IN THE CASCADE REFERENCE EFFICACY Strengths based case Improved linkage from Linkage to care Gardner 2005 management 60% to 78% Patient navigators Retention in care Bradford 2007 Clinic wide messaging Retention in care Gardner 2012 Contingency management Retention Clinic Linkage/retention, viral suppression Retention in care, viral suppression Project HOPE Project RETAIN Improved retention from 64% to 87% Improved retention by 10.4% Under study Under study Project Hope (CTN 0049) Population: HIV-infected drug users admitted to the hospital Outcome: Viral suppression i Interventions: Patient navigators Contingency management 12

Project Retain Population: HIV-infected crack users Outcome: Viral suppression Interventions: Patient navigators, substance abuse treatment Barriers to TasP (and what you can do about them) Lapses in the HIV care continuum Transmission during acute HIV infection 13

The special case of acute HIV infection HIV viral load P24 antigen HIV antibody 0 5 10 15 20 25 30 35 40 45 50 55 60 65 Days Adapted from Branson 2010 Addressing HIV transmission from acutely infected individuals Intensive contact tracing: David Goudreau, DPH Division of STD Prevention, 617-983-6835 Can be available when the diagnosis is given 14

Hallmarks of Acute Infection Features of Acute Infection Percent of Patient Fever 75 Rash 48 Headache 45 Pharyngitis 40 Cervical LAD 39 Diarrhea 27 HIV Test Results Consistent with Acute Infection Positive viral load*, negative EIA, negative Western blot Positive viral load*, positive EIA, negative Western blot *HIV viral load should be high in acute infection. Daar 2008 Addressing HIV transmission from acutely infected individuals Intensive contact tracing: David Goudreau, DPH Division of STD Prevention, 617-983-6835 Can be available when the diagnosis is given Other preventive measures: Safer sex, condoms Pre-exposure exposure prophylaxis (PrEP) 15

Pre-Exposure Prophylaxis (PrEP) PrEP works (but adherence is vital) Trial Agent Population Risk Reduction MSM, iprex TDF-FTC transgender women 44% TDF2-CDC Partners PrEP TDF-FTC TDF, TDF-FTC Heterosexual men and women 62.2% Heterosexual couples FEM-PrEP PEP TDF-FTCFTC Women --- VOICE TDF-FTC Women --- ( TDF-FTC = tenofovir-emtricitabine) 75% TDF-FTC, 67% TDF Adapted from van der Straten 2012 16

Better adherence = better efficacy Courtesy of Doug Krakower PrEP is safe for most patients No major safety concerns in PrEP trials Nausea more common with TDF-FTC FTC than placebo No difference in creatinine elevations or bone fractures (potential TDF toxicities) No risk compensation 17

The PrEP Package Determine eligibility: Document a negative HIV test Confirm high risk of infection Check that the creatinine clearance is 60 ml/minute Other steps: Check a pregnancy test Check for chronic hepatitis B infection CDC 2012 18

Prescribe: TDF-FTC, 1 tablet by mouth daily While on PrEP: Check an HIV test, pregnancy test, and creatinine every 2-3 months* Assess for STIs at least every 6 months Counsel regarding risk reduction and adherence; provide condoms *Initially, then creatinine can be checked every 6 months CDC 2012 Questions and Controversies What is the lower limit of adherence? What level of risk warrants PrEP? Who should prescribe it? 19

Back to our case: 26M at high risk of HIV infection Counseled that his main partner s use of ART likely reduces the risk of transmission to him Elected to begin PrEP with tenofoviremtricitabine to further reduce risk Remains HIV-uninfected to date Condom use is still inconsistent; i t he has had repeated episodes of rectal gonorrhea Summary HIV prevention is a key area of collaboration between public health and primary care. Lapses in the HIV care cascade prevent full realization of the benefits of treatment as prevention. Primary care providers can improve the cascade through universal testing and treatment, efforts to engage patients in care, and treatment of substance abuse and mental illness. PrEP is a powerful HIV prevention tool for highrisk individuals, but adherence is vital. 20

Thank You Kevin L. Ard, MD MPH Brigham and Women s Hospital kard@partners.org 21